HC Wainwright restated their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a report released on Tuesday morning. They currently have a $33.00 price objective on the biopharmaceutical company’s stock.
Other analysts also recently issued research reports about the stock. BidaskClub upgraded shares of TG Therapeutics from a sell rating to a hold rating in a research report on Thursday, January 11th. Raymond James Financial reaffirmed a buy rating on shares of TG Therapeutics in a report on Tuesday, December 12th. ValuEngine cut shares of TG Therapeutics from a hold rating to a sell rating in a report on Monday, October 16th. B. Riley reaffirmed a buy rating and issued a $21.50 target price on shares of TG Therapeutics in a report on Monday, December 11th. Finally, SunTrust Banks reaffirmed a buy rating and issued a $28.00 target price on shares of TG Therapeutics in a report on Tuesday, October 3rd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. TG Therapeutics has a consensus rating of Buy and an average target price of $25.50.
Shares of TG Therapeutics (NASDAQ TGTX) traded up $0.07 during trading hours on Tuesday, hitting $9.63. 433,335 shares of the stock traded hands, compared to its average volume of 1,672,810. The stock has a market cap of $678.26, a P/E ratio of -4.99 and a beta of 1.30. TG Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.35.
In other news, CFO Sean A. Power sold 32,006 shares of TG Therapeutics stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total value of $272,051.00. Following the transaction, the chief financial officer now directly owns 517,464 shares of the company’s stock, valued at approximately $4,398,444. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 16.70% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. State Street Corp increased its stake in TG Therapeutics by 274.4% in the 2nd quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock valued at $26,515,000 after buying an additional 1,933,896 shares during the period. Franklin Resources Inc. increased its stake in TG Therapeutics by 20.6% in the 2nd quarter. Franklin Resources Inc. now owns 2,339,166 shares of the biopharmaceutical company’s stock valued at $23,509,000 after buying an additional 398,916 shares during the period. Vanguard Group Inc. increased its stake in TG Therapeutics by 14.3% in the 2nd quarter. Vanguard Group Inc. now owns 2,046,427 shares of the biopharmaceutical company’s stock valued at $20,566,000 after buying an additional 255,844 shares during the period. Columbus Circle Investors increased its stake in TG Therapeutics by 9.8% in the 3rd quarter. Columbus Circle Investors now owns 1,532,911 shares of the biopharmaceutical company’s stock valued at $18,165,000 after buying an additional 136,515 shares during the period. Finally, Northern Trust Corp increased its stake in TG Therapeutics by 29.0% in the 2nd quarter. Northern Trust Corp now owns 598,626 shares of the biopharmaceutical company’s stock valued at $6,016,000 after buying an additional 134,463 shares during the period. 50.41% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This story was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://weekherald.com/2018/01/17/tg-therapeutics-tgtx-receives-buy-rating-from-hc-wainwright-2.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.